CTLA4 and cancer: Monoclonal antibodies targeting cytotoxic T lymphocytes‐associated antigen 4 (CTLA4), programed death‐1 (PD‐1) receptor, and its ligand (PD‐L1) have achieved clinical success in some cancers.13, 14, 15